The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

DSpace/Manakin Repository

The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

Show simple item record

dc.contributor.author Pater, J.
dc.contributor.author Richardson, H
dc.contributor.author Johnston, D.
dc.contributor.author Goss, Paul E.
dc.date.accessioned 2011-03-11T20:53:52Z
dc.date.issued 2007
dc.identifier.citation Richardson, H., D. Johnston, J. Pater, and Paul E. Goss. 2007. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Current Oncology 14(3): 89-96. en_US
dc.identifier.issn 1198-0052 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4741070
dc.description.abstract Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has developed a randomized phase iii study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The ncic ctg map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene. en_US
dc.language.iso en_US en_US
dc.publisher Multimed Inc. en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899358/pdf/ en_US
dash.license LAA
dc.subject aromatase inhibitors en_US
dc.subject breast cancer risk reduction en_US
dc.subject chemoprevention en_US
dc.title The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Current Oncology en_US
dash.depositing.author Goss, Paul E.
dc.date.available 2011-03-11T20:53:52Z
dash.affiliation.other HMS^Medicine-Massachusetts General Hospital en_US

Files in this item

Files Size Format View
1899358.pdf 60.57Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters